Classification of 
neuroendocrine tumors

There are a number of factors, including site of origin, clinical syndrome, grade and differentiation, staging, extent of disease, and imaging tests, that can help health care professionals classify neuroendocrine tumors (NET).1,2

Correct NET classification can facilitate accurate diagnosis and may lead to better patient outcomes3

Site of origin

**Foregut**4,5
- Lungs
- Stomach
- First part of duodenum
- Pancreas

**Midgut**4
- Second part of duodenum
- Jejunum
- Ileum
- Right colon

**Hindgut**4
- Transverse, left, and sigmoid colon
- Rectum

**Additional sites**3,6
- Ovary
- Adrenal gland
- Paraganglia
- Thymus
- Appendix

Clinical syndrome

**NONFUNCTIONAL**
- Tumors that do not secrete active hormones and do not produce hormone-related symptoms1
- Symptoms, if present, are related to tumor mass1,7,8
- Majority of NET9
- Tend to be more aggressive and often present after metastases10

**FUNCTIONAL**
- Tumors that secrete active hormones and produce hormone-related symptoms1
- Symptoms are related to the excess production of hormones1
- Minority of NET9
- Tend to be slow growing10

NET can be functional (tumors that secrete hormones) or nonfunctional (tumors that do not secrete hormones)1
Pathology

NET can be well-differentiated, moderately differentiated, or poorly differentiated, and over half of NET originate in the GI tract. A complete GI NET pathology report can include site of origin, diagnosis, histological features, IHC staining, grade (proliferation, determined by mitotic rate or Ki-67), and other pathological components. A GI NET pathology report includes:

<table>
<thead>
<tr>
<th>Well-differentiated NET (Low grade, G1)(^6)</th>
<th>Well-differentiated NET (Intermediate grade, G2)(^6,12)</th>
<th>Poorly differentiated NEC (High grade, G3)(^6)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Appearance(^12)</td>
<td>*</td>
<td>Cellular pleomorphism</td>
</tr>
<tr>
<td>Prognosis(^12)</td>
<td>Intermediate</td>
<td>Poor</td>
</tr>
<tr>
<td>Mitotic rate(^6)</td>
<td>&lt;2 mitoses/10 HPF</td>
<td>&gt;20 mitoses/10 HPF</td>
</tr>
<tr>
<td>Ki-67 index(^6)</td>
<td>&lt;3%</td>
<td>3%-20%</td>
</tr>
<tr>
<td></td>
<td></td>
<td>&gt;20%</td>
</tr>
</tbody>
</table>

*Not well-defined in the medical literature.

Staging\(^13,14\)

TNM staging is a classification system based on 3 factors:

<table>
<thead>
<tr>
<th>TUMOR (T):</th>
<th>NODE (N):</th>
<th>METASTASIS (M):</th>
</tr>
</thead>
<tbody>
<tr>
<td>Size and location of the primary tumor</td>
<td>Whether cancer cells have spread to the lymph nodes located near the tumor</td>
<td>Whether the tumor has spread to other parts of the body</td>
</tr>
</tbody>
</table>

The definition of TNM may vary by primary tumor site, but staging relies predominantly on tumor size and extent of invasion into anatomical structures.

Abbreviations: HPF, high-power field; IHC, immunohistochemical; NEC, neuroendocrine carcinoma.
Extent of disease

- **Localized**: tumors contained within the organ of origin
- **Regional**: tumors that have spread through the organ wall to nearby tissues
- **Distant**: tumors that have spread beyond primary site to distant tissues and/or organs

Imaging tests

Imaging tests can be helpful to detect and localize NET. Many NET are detected incidentally through routine imaging tests for unrelated problems.

- Computed tomography (CT)
- Magnetic resonance imaging (MRI)
- Somatostatin receptor scintigraphy (SRS) (Octreoscan™), as appropriate
- Ga 68 dotatate PET
- Endoscopic ultrasound (EUS)
- Endoscopy
- Colonoscopy
- Bronchoscopy
- Esophagogastroduodenoscopy (EGD)

References:

6. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Neuroendocrine and Adrenal Tumors V1.2018. © National Comprehensive Cancer Network, Inc 2018. All rights reserved. Accessed April 3, 2018. To view the most recent and complete version of the guideline, go online to NCCN.org. The National Comprehensive Cancer Network makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.